Spoken Alpha
AVENUE THERAPEUTICS, INC.
Avenue Therapeutics develops specialty pharmaceutical treatments for neurologic diseases, including ATX-04, a selective β2-adrenergic agonist for Pompe disease, and intravenous tramadol, a Schedule IV opioid for post-operative acute pain.
AVENUE THERAPEUTICS, INC is a Healthcare company operating in Biotechnology with a $1.8M market cap.
Most recent reported earnings: Q3 FY2025 (Nov 12, 2025).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add ATXI, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ATXI.
$ curl https://api.spokenalpha.com/v1/companies/ATXIFAQ
Spoken Alpha indexes ATXI's earnings call transcripts at https://spokenalpha.com/companies/ATXI. Each call links to attributed speakers and parsed analyst Q&A. AVENUE THERAPEUTICS, INC.'s own investor relations page is at https://ir.avenuetx.com/.
AVENUE THERAPEUTICS, INC. (ATXI) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2025 | 2025-11-12 | $-0.21 | $0.00 | — | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $0.11 | — | — | $1.4M | — | — | EODHD |
| Q1 FY2025 | 2025-05-12 | $-0.73 | $-9.00 | +91.9% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-30 | $3.83 | $-0.09 | +100.0% | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-11-13 | $-1.92 | $-0.94 | -100.0% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-08 | $-2.41 | $-1.05 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-14 | $-15.40 | $-9.00 | -71.1% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-17 | $0.06 | $-0.10 | +100.0% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $4.50 | $-19.50 | +100.0% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-39.00 | $-21.75 | -79.3% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-11 | $-1.35 | $-0.13 | -100.0% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-29 | $-98.93 | $-56.25 | -75.9% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-33.75 | $-56.25 | +40.0% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-14 | $-0.03 | $-0.60 | +95.0% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-15 | $-0.05 | $-0.04 | -25.0% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-24 | $-0.05 | $-0.04 | -25.0% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-14 | $-56.25 | $-56.25 | 0.0% | $0 | — | — | EODHD |
| Q2 FY2021 | 2021-08-15 | $-67.50 | $-67.50 | 0.0% | $0 | — | — | EODHD |
| Q1 FY2021 | 2021-05-16 | $-67.50 | $-56.25 | -20.0% | $0 | — | — | EODHD |
| Q4 FY2020 | 2021-03-30 | $-0.90 | $-0.90 | 0.0% | $0 | — | — | EODHD |
Source: EODHD. ATXI reported actuals as published; sparse fields render as —.